1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61E348EC09DB5597900258BEA003F2E67
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/1E348EC09DB5597900258BEA003F2E67?OpenDocument
18
19OpenDocument
2018.97.14.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Launch Optimization

Document Excerpt: Interweaving Medical Strategy to Maximize New Treatment Success: Medical Affairs Launch Resourcing Benchmarks

DB Image

ID: MD-941


Features:

4 Info Graphics

12 Data Graphics

140+ Metrics

4 Narratives


Pages/Slides: 4


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5841 “Interweaving Medical Strategy to Maximize New Treatment Success: Medical Affairs Launch Resourcing Benchmarks”.

Industries Profiled:
Biotech; Pharmaceutical; Biopharmaceutical; Health Care; Clinical Research; Laboratories


Companies Profiled:
Chimerix; Corcept Therapeutics; Dermavant Sciences; Eisai; EMD Serono; Ferrer; Grifols; GlaxoSmithKline ; Galderma; Jazz Pharmaceuticals; KalVista Pharmaceuticals; Merz Aesthetics; OTSUKA; Sanofi; Santen; Takeda Pharmaceuticals; Vertex Pharmaceuticals; Zambon

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.